Clinical Study On The Prevention Of Cardiotoxicity Of Anthracycline Chemotherapy Drugs In Breast Cancer By Crocin

Objective:To study the clinical research of Crocin to prevent the cardiotoxicity of anthracycline chemotherapy drugs after breast cancer surgery,and to actively intervene and prevent breast cancer-related cardiovascular subclinical damage at an early stage.Methods:Selected patients who met the inclusion criteria and received Aanthracycline-containing chemotherapy,and were randomly divided into the treatment group(n=31)and the control group(n=29).The treatment group started oral administration of Crocin 1 week before chemotherapy,4tablets per time,3 times a day,after meals,for 2 consecutive weeks.The control group received no drug intervention.Before chemotherapy,after1 cycle,2 cycles,and4 cycles of chemotherapy,the cardiotoxicity performance,cardiac function,electrocardiogram performance,TCM syndrome score,LVEF,CTn I,BNP,CK,CK-MB and safety of the two groups of patients were compared.Sexual indicators are evaluated.Results:(1)Cardiotoxicity grading standard:There were statistically significant differences between the two groups in terms of rhythm and cardiac function after 4 cycles of chemotherapy and after 2 cycles of chemotherapy(P<0.05);there was no pericarditis event.(2)Standard assessment of cardiac function:after 2 cycles and 4 cycles of chemotherapy,the cardiac function of the treatment group was better than that of the control group,with statistical difference(P<0.05);(3)TCM main syndrome score:in terms of palpitations,asthma,chest tightness and other symptoms,the improvement degree of the treatment group was better than that of the control group(P<0.05);(4)ECG:both groups had abnormal ECG,but the incidence of abnormal ECG in the treatment group was lower than that in the control group group(P<0.05);(5)LVEF:there was no statistical significance in the two groups after 1 and 2 cycles of chemotherapy(P>0.05);after 4 cycles of chemotherapy,the LVEF level of the treatment group was higher than that of the control group,with statistical significance(P<0.05);(6)Markers of myocardial injury:the levels of CTn I and BNP in the treatment group were significantly better than those in the control group after 4 cycles of chemotherapy(P<0.05);CK and CK-MB were not statistically significant Significance(P>0.05).No abnormality was found in the safety observation indicators.Conclusion:Crocin can be used to prevent the cardiotoxicity of anthracycline chemotherapy drugs after breast cancer surgery,improve the symptoms of some patients with cardiac diseases,reduce the probability of cardiotoxicity,help patients establish self-confidence,and improve their quality of life.As a potential drug for the prevention of anthracycline-containing oncological cardiology.